Chronic upper limb ischemia is uncommon, and is most often secondary to subclavian artery stenosis. Percutaneous intervention for subclavian stenosis usually includes balloon angioplasty and stent implantation. Brachial artery stenosis is even more scarce and accounts for approximately 12% of symptomatic upper extremity ischemia. Because it is rare, the optimal treatment strategy for brachial artery stenosis remains uncertain. We describe a case of chronic brachial artery ischemia due to atherosclerotic disease treated with the SilverHawk™ plaque excision system and review the available data regarding its use.
Introduction
Chronic upper limb ischemia is uncommon and usually secondary to subclavian artery stenosis. 1 The symptoms of chronic upper limb ischemia depend upon the location of the obstructive lesion and include arm weakness, arm claudication, vertigo subsequent to subclavian steal syndrome, and, in the case of patients who have undergone coronary artery bypass surgery, angina. Intervention for subclavian artery disease most commonly includes balloon angioplasty and stent implantation. 2 Chronic brachial artery atherosclerotic occlusive disease causes approximately 12% of symptomatic upper extremity ischemia. 3 Since chronic brachial artery stenosis is rare, the optimal management strategy is unclear. Endovascular management offers a less invasive approach compared with bypass surgery. Endovascular techniques include balloon angioplasty, stent implantation and, most recently, directional atherectomy.
The SilverHawk™ plaque excision system (Foxhollow Technologies, Menlo Park, CA, USA) is an FDA-approved device for the treatment of peripheral arterial disease. It allows simultaneous plaque excision with a spinning carbide cutter and plaque retrieval using a distal nosecone collection chamber. It is most commonly used in infrainguinal revascularization procedures. We describe the first use of the Silverhawk plaque excision system for treatment of chronic brachial artery ischemia due to atherosclerotic disease.
Case history
A 52-year-old man with hypertension, hyperlipidemia and remote tobacco abuse, who had undergone multiple peripheral vascular interventions, including stent placement in his brachiocephalic artery, described recurrent right arm claudicative symptoms 1 year following the proximal revascularization. Angiographically, no flowlimiting disease was noted in the right subclavian artery. The right brachial artery had a 100% lesion with moderate calcification ( Figure 1A ) and normal brachial artery flow distally ( Figure 1B) .
One month later, the patient returned for planned revascularization of the right brachial artery. Access was initially obtained in the right brachial artery distal to the occlusion. Attempts to cross the occlusion in a retrograde fashion using an angled Glidewire™ (Terumo, Somerset, NJ, USA) were unsuccessful. Therefore, access was obtained in the right common femoral artery. A Berenstein catheter (Angiodynamics, Queensbury, NY, USA) was advanced to the proximal portion of the right brachial artery, and the occlusion was crossed in an antegrade fashion using a soft angled Glidewire. A Quickcross™ catheter (Spectranetics Corp., Colorado Springs, CO, USA) was positioned in the brachial artery distal to the occlusion. The wire was then directed into the brachial artery sheath and externalized. Next, the Quickcross catheter was advanced across the occlusion over the Glidewire, which was then exchanged for a Spartacore™ wire (Boston Scientific, Natick, MA, USA). Angiography again revealed a near-complete occlusion of the brachial artery ( Figure 2A ). Atherectomy was performed with the SilverHawk medium vessel standard tip (MSF) for two passes and large vessel standard flush tip (LSF) device for one pass with excellent angiographic debulking and a 30% residual stenosis ( Figure 2B ). Adjunctive balloon angioplasty was performed using a 5.0 ϫ 20 mm Submarine Plus™ balloon (ev3, Inc., Plymouth, MN, USA) at 4 atmospheres. Final angiography demonstrated no dissection, minor residual stenosis (Ͻ 10%), and normal flow with no demonstrable gradient across the lesion ( Figure 2C) .
Doppler waveform analysis of the extremity performed 2 weeks after the procedure revealed triphasic waveforms at the brachial, radial, and ulnar arteries. Three months after the procedure, the patient had no symptoms of arm claudication and remained clinically stable.
Discussion
The concept of removing offending atherosclerotic plaque in cardiovascular disease first began in the 1980s and was intended for the treatment of de novo coronary artery disease or proximal bifurcation disease in the early balloon angioplasty era. 4 Directional coronary atherectomy demonstrated acute angiographic benefit 5, 6 but no advantage in reducing clinical events. 7 Owing to the absence of a dominant standard for endovascular revascularization of infra-inguinal peripheral arterial disease, there has been resurgence in the use of atherectomy in this anatomic region. Atherectomy adds an attractive option to the abundant array of procedures for treatment of symptomatic peripheral arterial disease 8 because it does not introduce permanent endoprostheses into these dynamic arteries. Since symptomatic distal arterial upper limb ischemia represents only a minority of patients with peripheral arterial disease, data regarding the optimal endovascular management are sparse. Therefore, management strategies used in lower limb ischemia are often applied to the upper extremity.
Two randomized trials have compared atherectomy using the Simpson Atherocath™ with balloon angioplasty for the treatment of peripheral arterial disease in a total of 104 patients. 9, 10 Neither reported any additional benefit, either angiographically or clinically, with atherectomy, and the combined outcomes favored balloon angioplasty alone.
The SilverHawk device, however, is fundamentally different in design. The Simpson Atherocath used a balloon to fix the device in the target vessel. The carbide blade in the Silverhawk device is exposed at a fixed height during atherectomy and apposes the atheroma through a two-part proximal bend in the shaft and a hinge system at the cutter device. Although the SilverHawk stores excised atheroma in its nosecone, there is still evidence of embolization during its use. 11 Thus, it has been suggested that it may be prudent to use an embolic protection device when there is evidence of poor distal runoff.
There have been no randomized trials comparing the SilverHawk device with angioplasty and/or stent implantation, but there are a number of short-and long-term single-center and registry clinical data series evaluating its use in the lower limb.
A non-randomized registry of patients treated with SilverHawk atherectomy evaluated 84 patients with 131 lesions. 12 One-third of the lesions were de novo, one-third were restenoses following angioplasty and the remaining third were in-stent restenoses. Adjuvant ballooning was used in almost two-thirds and stents were used in less than 10% of lesions following atherectomy. The de novo lesions had the most impressive angiographic and clinical outcomes, with 84% patency (freedom from Ͼ 50% restenosis) by Doppler ultrasonography at 12 months and 73% patency at 18 months. Target vessel revascularization was required in just 16% of de novo lesions at 12 months. Results for restenoses and in-stent restenoses were not as favorable. Approximately half of the lesions were patent by Doppler ultrasonography at 12 and 18 months, with target vessel revascularization approaching 50% at 12 months.
While this was not a randomized study, these results compare favorably with a recent trial comparing nitinol stent placement with balloon angioplasty in de novo superficial femoral artery lesions. 13 Schillinger et al. reported 37% patency at 12 months with balloon angioplasty compared to 63% with nitinol stents by Doppler ultrasonography. A recent meta-analysis reported patency of 59% at 1 year and 45% at 5 years with balloon angioplasty. 1 Chronic brachial artery occlusion is uncommon, and the optimal endovascular treatment is unknown. There have been no randomized trials or large prospective series regarding endovascular therapy in this anatomic location. While there is a case report of atherectomy used as a diagnostic and therapeutic procedure in upper limb ischemia secondary to Takayasu's arteritis, 14 we present a novel approach for the treatment of chronic atherosclerotic brachial occlusion using atherectomy with the SilverHawk plaque excision system. Data from patients with chronic lower limb ischemia treated with SilverHawk atherectomy, as well as the immediate angiographic and short-term clinical success of the case presented, suggest that atherectomy may be a viable treatment for selected cases involving the upper extremity.
